Immunotherapy for Renal Cell Carcinoma—What More is to Come?
Yochum Z, Braun D. Immunotherapy for Renal Cell Carcinoma—What More is to Come? Targeted Oncology 2025, 20: 467-483. PMID: 40208564, DOI: 10.1007/s11523-025-01143-7.Peer-Reviewed Original ResearchConceptsICI-based regimensRenal cell carcinomaImmune checkpoint inhibitorsMetastatic renal cell carcinomaVEGFR-TKIsVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsClinical trialsAnti-PD-1 therapyAntitumor T-cell immunityImprove T-cell activationReceptor tyrosine kinase inhibitorsTreatment of renal cell carcinomaDurability of treatment responseFirst-line therapyPatient outcomesT cell immunityTyrosine kinase inhibitorsFDA-approved agentsT cell activationInnovative treatment strategiesCheckpoint inhibitorsCell carcinomaImprove patient outcomesTumor microenvironment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply